In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides

Nucleic Acids Research

Volumn 31, Issue 3, 2003, Pages 953-962

  Fluiter, Kees ^a   ten Asbroek, Anneloor L M A ^a   de Wissel, Marit B ^a   Jakobs, Marja E ^a   Wissenbach, Margit ^b   Olsson, Håkan ^b   Olsen, Otto ^b   Oerum, Henrik ^b   Baas, Frank ^a  

^a Santaris Pharma AS   (Denmark)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FOMIVIRSEN; LOCKED NUCLEIC ACID; NUCLEIC ACID; PHOSPHOROTHIOIC ACID DERIVATIVE; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG TARGETING; DRUG URINE LEVEL; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL DIVISION; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDES, ANTISENSE; RNA POLYMERASE II; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 0037326836     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkg185     Document Type: Review

References (30)

1. Dove,A. (2002) Antisense and sensibility. Nat. Biotechnol., 20, 121-124.
2. Hausen,P. and Stein,H (1970) Ribonuclease H, an enzyme degrading the RNA moiety of DNA-RNA hybrids. Eur. J. Biochem., 14, 278-283.
3. Agrawal,S. (1999) Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides Biochim. Biophys. Acta, 1489, 53-68.
4. Stein,C.A. (1999) Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Biochim. Biophys. Acta, 1489, 45-52.
5. Yu,R., Geary,R., Leeds,J., Watanabe,T., Moore,M., Fitchett,J., Matson,J., Burckin,T., Templin,M. and Levin,A. (2001) Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J. Pharm. Sci., 90, 182-193.
6. Stevenson,J.P., Yao,K.S., Gallagher,M., Friedland,D., Mitchell,E.P., Cassella,A., Monia,B., Kwoh,T.J., Yu,R., Holmlund,J. et al. (1999) Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol., 17, 2227-2236.
7. Dennis,J.U., Dean,N.M., Bennett,C.F., Griffith,J.W., Lang,C.M. and Welch,D.R. (1998) Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha. Cancer Lett., 128, 65-70.
8. Yuen,A.R., Halsey,J., Fisher,G.A., Holmlund,J.T., Geary,R.S., Kwoh,T.J., Dorr,A. and Sikic,B.I. (1999) Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res., 5, 3357-3363.
9. Yacyshyn,B.R., Bowen-Yacyshyn,M.B., Jewell,L., Tami,J.A., Bennett,C.F., Kisner,D.L. and Shanaban,W.R.,Jr (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's desease. Gastroenterology, 114, 1133-1142.
10. Braasch,D.A. and Corey,D.R. (2002) Novel antisense startegies for controlling gene expression. Biochemistry, 41, 4503-4510.
11. Dias,N. and Stein,C.A.(2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther., 1, 347-355.
12. Koshkin,A., Singh,S.K., Nielsen,P., Rajwanshi,V.K., Kumar,R., Melgaard,M., Olsen,C.E. and Wengel,J. (1998) LNA: synthesis of the adenine, cytosine, guanine 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation and unprecedented nucleic acid recognition. Tetrahedron, 54, 3607-3630.
13. Braasch,D.A. and Corey,D.R. (2001) Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol., 8, 1-7.
14. Elayadi,A.N. and Cory,D.R. (2001) Application of PNA and LNA oligomers to chemotherapy. Curr. Opin. Invest. Drugs, 2, 558-561.
15. Wahlestedt,C., Salmi,P., Good,L., Kela,J., Johnsson,T., Hokfelt,T., Broberger,C., Porreca,F., Lai,J., Ren,K. et al. (2000) Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl Acad. Sci. USA, 97, 5633-5638.
16. Kurreck,J., Wyszko,E., Gillen,C. and Erdmann,V.A. (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res., 30, 1911-1918.
17. Baker,B.F., Lot,S.S., Condon,T.P., Cheng-Flournoy,S., Lesnik,E.A., Sasmor,H.M. and Bennett,C.F. (1997) 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem., 272, 11994-12000.
18. Dias,N., Dheur,S., Nielsen,P.E., Gryaznov,S., Van Aerschot,A., Herdewijn,P., Helene,C. and Saison-Behmoaras,T.E. (1991) Antisense PNA tridecamers; targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J. Mol. Biol., 294, 403-416.
19. Arzumanov,A., Walsh,A.P., Rajwanshi,V.K., Kumar,R., Wengel,J. and Gait,M.J. (2001) Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry, 40, 14645-14654.
20. ten Asbroek,A.L., Fluiter,K., van Groenigen,M., Nooij,M. and Baas,F. (2000) Polymorphisms in the large subunit of human RNA polymerase II as target for allele-specific inhibition. Nucleic Acids Res., 28, 1133-1138.
21. Fluiter,K., ten Asbroek,A.L.M.A., van Groeningen,M., Nooij,M., Aalders,M.C.G. and Baas,F. (2002) Tumor genotype specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA Polymerase II. Cancer Res., 62, 2024-2028.
22. Graham,M.J., Freier,S.M., Crooke,R.M., Ecker,D.J., Maslova,R.N. and Lesnik,E.A. (1993) Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res., 21, 3737-3743.
23. Meyer,T., Regenass,U., Fabbro,D., Alteri,E., Rosel,J., Muller,M., Caravatti,G. and Matter,A. (1989) A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int. J. Cancer, 43, 851-856.
24. Bijsterbosch,M.K., Manoharan,M., Rump,E.T., De Vrueh,R.L., van Veghel,R., Tivel,K.L., Biessen,E.A., Bennett,C.F., Cook,P.D. and van Berkel,T.J. (1997) In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res., 25, 3290-3296.
25. Levin,A. (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta, 1489, 69-84.
26. Hirose,Y. and Manley,J.L.(2000) RNA polymerase II and the integration of nuclear events. Genes Dev., 14, 1415-1429.
27. Nguyen,V.T., Giannoni,F., Dubois,M.F., Seo,S.J., Vigneron,M., Dedinger,C. and Bensaude,O. (1996) In vivo degradation of RNA polymerase II largest subunit triggered by alpha-amanitin. Nucleic Acids Res., 24, 2924-2929.
28. McKay,B.C., Chen,F., Clarke,S.T., Wiggin,H.E., Harley,L.M. and Ljungman,M. (2001) UV light-induced degradation of RNA polymerase II is dependent on the Cockayne's syndrome A and B proteins but not p53 or MLH1. Mutat. Res., 485, 93-105.
29. Martinez,J., Patkaniowska,A., Urlaub,H., Luhrman,R. and Tuschl,T. (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 110, 563-574.
30. Petersen,M., Bondensgaard,K., Wengel,J. and Jacobsen,J.P. (2002) Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids. J. Am. Chem. Soc., 124, 5974-5982.